DENTSPLY SIRONA Inc vs 22nd Century Group Inc — how do they compare? DENTSPLY SIRONA Inc trades at $13.56 (market cap $2.70B), while 22nd Century Group Inc trades at $4.25 (market cap $1.49M). The key difference: DENTSPLY SIRONA Inc is far larger — about 1812.1× 22nd Century Group Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals.
| XRAY | XXII | |
|---|---|---|
Market Cap | $2.70B | $1.49M |
Sector | Health | Technology |
52-Week High | $16.85 | $1.07K |
52-Week Low | $9.64 | $3.90 |
Enterprise Value | $4.84B | -$6.74M |
Dividend Yield | 5.04% | — |
Signals from Pluang's Aura AI — not financial advice
Dentsply Sirona (XRAY) trades at $13.65, down 2.91% on the day, with a mixed technical picture showing a bullish moving average signal but overbought RSI levels. Fundamentally, the company reported a net loss of $598 million for 2025, with negative profit margins and an elevated EV/EBITDA of 91.48, though revenue remains stable near $3.7 billion. Recent news includes the appointment of a new CFO and expanded U.S. distribution partnerships, while the upcoming Q2 2026 earnings call on August 6 is a key near-term catalyst.
The outlook remains challenging due to persistent losses and margin pressure, offset by strategic growth initiatives. Investment opportunities lie in the company's market leadership and digital dentistry expansion, but risks include high debt levels, competitive pressures, and the need for a successful turnaround. Analyst consensus is Hold with a price target of $13.33, indicating limited near-term upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →